COGNISION™ for neurological disorders, including dementia

TECHNOLOGY

COGNISION™ is a new system developed by Neuronetrix to assist clinicians in the diagnosis and evaluation of Alzheimer's disease, related dementias and other neurological disorders.

The system is intended to non-invasively detect differences in the neural processing of auditory stimuli in people with neurological disorders.

The system records electrical signals at the scalp whilst a patient listens to a series of pre-determined sounds. Software is then used to evaluate these signals, known as event-related potentials (ERPs). COGNISION™ consists of a headset, software and an online electronic subject record system. The test takes approximately 30 minutes and the company states it could be administered by non-specialist personnel in an outpatient setting.

The COGNISION™ System is not yet CE marked and is currently being used in therapeutic clinical trials and cognitive research only. It is anticipated to be available in the UK in the next 18-24 months.

POTENTIAL FOR IMPACT

The company states that the COGNISION™ System provides an objective, physiologically-based, measure of cognitive function and may change patient management and health outcomes by allowing earlier diagnosis and treatment of neurological disorders such as Alzheimer's dementia.

They also state that doctors could use the test to help determine which patients would benefit from available drug treatments and to monitor the efficacy of the prescribed therapy.

Early diagnosis of dementia may mean treatment is started earlier, which may help someone stay independent longer. It also means treatment may be more cost-effective. Staff training would be required.
EVIDENCE

COMPLETED STUDIES (UNPUBLISHED)

ONGOING STUDIES

INFORMATION FROM
This Alert is based on information from the company and a time-limited internet search.